Kyverna Therapeutics (KYTX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
27 May, 2026Opening remarks and agenda
2026 described as a pivotal year with transition to commercial stage and regulatory progress for mivocabtagene in autoimmune diseases.
Meeting called to order with CEO as Chairman and CFO as Secretary; introduction of independent auditor from BDO USA.
Agenda included election of two Class II directors and ratification of the independent auditor.
Board and executive committee updates
Board nominated Ian Clark and Christi Shaw for re-election as Class II directors, with no other nominations received.
Shareholder proposals
No shareholder proposals were received for this year's meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Kyverna Therapeutics
- Miv-cel achieved durable, drug-free remission in SPS and gMG with strong safety and commercial outlook.KYTX
Corporate presentation - Q2 2026 net loss narrowed to $38.3M as miv-cel advanced with FDA RMAT and strong cash reserves.KYTXQ2 2026
- KYV-101 demonstrates transformative efficacy in autoimmune diseases, with pivotal data expected in 2026.KYTXJefferies London Healthcare Conference 2025
- Strong clinical data and FDA alignment position for first CAR T launch in autoimmune diseases.KYTXJefferies Global Healthcare Conference 2026
- Miv-cel delivers durable, drug-free remission in SPS and gMG with strong safety and market potential.KYTXCorporate presentation
- Transformative CAR-T therapy for SPS nears launch, with expansion into MG and MS underway.KYTXH.C. Wainwright 4th Annual BioConnect Investor Conference
- Miv-cel delivers durable, drug-free remission in SPS and gMG with strong safety and scalability.KYTXInvestor presentation
- Rolling BLA for miv-cel in SPS underway, strong trial results, and solid cash position.KYTXQ1 2026
- Miv-cel achieved robust efficacy and safety in SPS, supporting a 2026 FDA submission.KYTXStudy Result